Role and mechanism of type I interferon in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis
Not Applicable
Recruiting
- Conditions
- Anti-MDA5 antibody-positive dermatomyositis
- Registration Number
- JPRN-UMIN000049776
- Lead Sponsor
- Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients or health controls who cannot give consent. 2) Patients or health controls who are unable to collect specimens. 3) Patients or health controls who are eligible to opt-out and who have requested to opt-out 4) Patients or health controls with other diseases or conditions that are considered inappropriate for this study. 5) Healthy controls with a history of connective tissue disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We will conduct an analysis of the correlation between serum interferon activity and clinical manifestations, hematological findings, severity of interstitial lung disease (ILD), and outcomes in MDA5-DM patients. Additionally, using various clinical indicators, we will perform latent cluster analysis to establish a novel disease classification by examining the association between disease subtypes and serum interferon levels. The measurement of interferon will be performed using the WISH IFN bioassay (Genes Immun 2007;8:492), which allows for the detection of serum interferon activity at approximately 100 times the sensitivity of conventional ELISA. Furthermore, we will use the ultra-sensitive digital ELISA method for interferon detection.
- Secondary Outcome Measures
Name Time Method